Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 27, 2017
April 06 2017 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it
will report its first quarter financial results on Thursday, April
27, 2017, after the close of financial markets. Following the
results announcement, company management will host a conference
call and webcast discussion of the results and provide a general
corporate update. Access to the event can be obtained as
follows:
LIVE access on Thursday, April 27, 2017
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
- Telephone 888-283-6901 (domestic) or
719-325-2217 (international); conference ID 8468596
- Webcast available at
www.seattlegenetics.com in the Investors and News section
REPLAY access
- Telephone replay will be available
beginning at approximately 4:30 p.m. PT on Thursday, April 27,
2017, through 5:00 p.m. PT on Monday, May 1, 2017, by calling
888-203-1112 (domestic) or 719-457-0820 (international); conference
ID 8468596
- Webcast replay will be available on the
Seattle Genetics website at www.seattlegenetics.com in the
Investors and News section
About Seattle Genetics
Seattle Genetics is an innovative biotechnology company that
develops and commercializes novel antibody-based therapies for the
treatment of cancer. The company’s industry-leading antibody-drug
conjugate (ADC) technology harnesses the targeting ability of
antibodies to deliver cell-killing agents directly to cancer cells.
ADCETRIS® (brentuximab vedotin), the company’s lead product, in
collaboration with Takeda Pharmaceutical Company Limited, is the
first in a new class of ADCs commercially available globally in 66
countries for relapsed classical Hodgkin lymphoma (HL) and relapsed
systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics
is also advancing vadastuximab talirine (SGN-CD33A; 33A), an ADC in
a phase 3 trial for acute myeloid leukemia. Headquartered in
Bothell, Washington, Seattle Genetics has a robust pipeline of
innovative therapies for blood-related cancers and solid tumors
designed to address significant unmet medical needs and improve
treatment outcomes for patients. The company has collaborations for
its proprietary ADC technology with a number of companies including
AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and
Pfizer. More information can be found at
www.seattlegenetics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170406005197/en/
Seattle Genetics, Inc.Investors:Peggy Pinkston,
425-527-4160ppinkston@seagen.comorMedia:Brandi Robinson,
425-527-2910brobinson@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024